Michael Rafii, Md, Phd

This study tests whether donanemab can safely reduce amyloid plaques in the brains of adults with Down syndrome, who are at high risk for Alzheimer's disease. Sixty participants aged 35-50 will receive either donanemab or a placebo every 4 weeks for 12 months, followed by a 12-mo…